- Home
- / Solvonis Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Solvonis Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
£0
2024-10-29
Market Capitalization
£3.1 M
2024-10-29
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| GBP | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 29.0K | 330.0K | 219.0K | 22.1M | 587.0K | |||
| Cost of goods sold | 13.0K | 46.0K | 118.0K | 9.1M | 329.0K | |||
| Gross profit | 16.0K | 284.0K | 102.0K | 13.0M | 258.0K | |||
| Gross profit margin, % | 55.2% | 86.1% | 46.6% | 58.9% | 44.0% | |||
| Operating expense total | 397.0K | 618.0K | 620.0K | 946.0K | 12.3M | 2.4M | 1.5M | 2.4M |
| Depreciation and amortization | 8.0K | 69.0K | 114.0K | 102.0K | 2.6M | 179.0K | 2.3M | |
| EBITDA | (397.0K) | (602.0K) | (336.0K) | (844.0K) | 732.0K | (2.1M) | (1.5M) | (2.4M) |
| EBITDA margin, % | -2075.9% | -101.8% | -385.4% | 3.3% | -357.8% | |||
| EBIT | (405.0K) | (671.0K) | (450.0K) | (946.0K) | (1.9M) | (2.3M) | (1.4M) | (4.7M) |
| EBIT margin, % | -2313.8% | -136.4% | -432.0% | -8.6% | -388.2% | |||
| Interest expense | 16.0K | 72.0K | 8.0K | 324.0K | 3.0K | 64.0K | ||
| Pre tax profit | (494.0K) | (703.0K) | (538.0K) | (954.0K) | (2.2M) | (3.1M) | (1.4M) | (5.7M) |
| Income tax expense | (736.0K) | |||||||
| Net Income | (494.0K) | (703.0K) | (538.0K) | (954.0K) | (1.5M) | (3.1M) | (1.4M) | (5.7M) |